TOKYO , Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO ® ) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10 .

Key presentations include results from the Phase Ib clinical study exploring the efficacy (Proof of Mechanism) of E2086 in people diagnosed with narcolepsy type 1 (NT1) and the Phase IV clinical study (SELENADE Study) investigating the effect of lemborexant in people whose insomnia was comorbid with depressive episodes of major depressive disorder and bipolar disorder (Poster 3-133). The company will also host a symposium introducing the latest evidence on lemborexant in Asia .

Eisai considers neurology, including sleep disorders such as insomnia and narcolepsy, as a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Oral Presentations

Poster Presentations

Eisai-Sponsored Symposium: RISE – Regional Insights in Sleep Excellence
Sep.8 (Mon.) 12:45-13:45 PM

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

[Notes to editors]

1. About lemborexant (product name: DAYVIGO)
   Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in more than 25 countries including Japan , the United States , China , Canada , Australia and countries in Asia and the Middle East .
   
   
2. About E2086
   E2086 is Eisai's in house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Individuals with a deficiency of orexin demonstrate excessive daytime sleepiness (EDS), as exemplified by patients with narcolepsy Type 1, demonstrate a loss of orexinergic neurons, and low cerebrospinal fluid (CSF) orexin levels. E2086 has the potential to improve patients' symptoms by enhancing orexin receptor activity.
   
   
3. About narcolepsy
   Narcolepsy is a chronic sleep disorder with that is characterized by EDS. Narcolepsy is classified into two subtypes, type 1 (narcolepsy with cataplexy) and type 2 (narcolepsy without cataplexy). Disease burden is high because of problems with fatigue, cognition, and persistence of residual symptoms despite treatment. 1

View original content to download multimedia: https://www.prnewswire.com/news-releases/eisai-to-present-latest-data-on-lemborexant-and-novel-orexin-receptor-agonist-e2086-at-the-world-sleep-2025-302545764.html

SOURCE Eisai Inc.